[川崎病应用阿司匹林的儿科专家共识]
[Pediatric expert consensus on the application of aspirin in Kawasaki disease].
出版信息
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Jun 15;24(6):597-603. doi: 10.7499/j.issn.1008-8830.2203190.
Abstract
Kawasaki disease (KD) is one of the common acquired heart diseases in children aged <5 years and is an acute systemic vasculitis. After nearly 60 years of research, intravenous immunoglobulin combined with oral aspirin has become the first-line treatment for the prevention of coronary artery lesion in acute KD; however, there are still controversies over the role and optimal dose of aspirin. The consensus was formulated based on the latest research findings of KD treatment in China and overseas and comprehensive discussion of pediatric experts in China and put forward recommendations on the dose, usage, and course of aspirin treatment in the first-line treatment of KD.
摘要
川崎病（KD）是5岁以下儿童常见的后天性心脏病之一，是一种急性全身性血管炎。经过近60年的研究，静脉注射免疫球蛋白联合口服阿司匹林已成为预防急性KD冠状动脉病变的一线治疗方法；然而，阿司匹林的作用和最佳剂量仍存在争议。本共识基于国内外KD治疗的最新研究结果以及国内儿科专家的全面讨论而制定，针对KD一线治疗中阿司匹林治疗的剂量、用法和疗程提出了建议。
相似文献
1
[Pediatric expert consensus on the application of aspirin in Kawasaki disease].[川崎病应用阿司匹林的儿科专家共识]
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Jun 15;24(6):597-603. doi: 10.7499/j.issn.1008-8830.2203190.
2
Pediatric expert consensus on the application of glucocorticoids in Kawasaki disease.川崎病糖皮质激素应用的儿科专家共识
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Mar 15;24(3):225-231. doi: 10.7499/j.issn.1008-8830.2112033.
3
Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease.陕西省川崎病诊疗中心。
Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(9):867-876. doi: 10.7499/j.issn.1008-8830.2107110.
4
Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease: Study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial.不同剂量阿司匹林联合免疫球蛋白（DAPI）预防川崎病冠状动脉异常：一项多中心、前瞻性、随机、开放标签、盲终点、非劣效性试验的研究方案。
Am Heart J. 2024 Jul;273:1-9. doi: 10.1016/j.ahj.2024.03.010. Epub 2024 Mar 19.
5
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.英夫利昔单抗强化川崎病一线治疗：一项 3 期随机、双盲、安慰剂对照试验。
Lancet. 2014 May 17;383(9930):1731-8. doi: 10.1016/S0140-6736(13)62298-9. Epub 2014 Feb 24.
6
Kawasaki disease: a comprehensive review of treatment options.川崎病：治疗选择的全面综述
J Clin Pharm Ther. 2015 Dec;40(6):620-5. doi: 10.1111/jcpt.12334. Epub 2015 Nov 7.
7
High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.高剂量阿司匹林与贫血相关，且对川崎病的疾病转归无益处。
PLoS One. 2015 Dec 10;10(12):e0144603. doi: 10.1371/journal.pone.0144603. eCollection 2015.
8
Kawasaki Disease: Beyond IVIG and Aspirin.川崎病：超越静脉注射免疫球蛋白和阿司匹林
Pediatr Ann. 2019 Oct 1;48(10):e400-e405. doi: 10.3928/19382359-20190919-01.
9
Effect of different doses of aspirin on the prognosis of Kawasaki disease.不同剂量阿司匹林对川崎病预后的影响。
Pediatr Rheumatol Online J. 2020 Jun 11;18(1):48. doi: 10.1186/s12969-020-00432-x.
10
Pathogenesis and management of Kawasaki disease.川崎病的发病机制与治疗管理。
Expert Rev Anti Infect Ther. 2010 Feb;8(2):197-203. doi: 10.1586/eri.09.109.
引用本文的文献
1
[DeepSeek perspective on managing Kawasaki disease in Chinese children].[DeepSeek对中国儿童川崎病管理的观点]
Zhongguo Dang Dai Er Ke Za Zhi. 2025 May 15;27(5):524-528. doi: 10.7499/j.issn.1008-8830.2502042.
2
[Evidence-based guidelines for the diagnosis and treatment of Kawasaki disease in children in China (2023)].《中国儿童川崎病诊断与治疗循证指南（2023年版）》
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Dec 15;25(12):1198-1210. doi: 10.7499/j.issn.1008-8830.2309038.
3
[Diagnosis and treatment of incomplete Kawasaki disease in children].[儿童不完全川崎病的诊断与治疗]
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Mar 15;25(3):238-243. doi: 10.7499/j.issn.1008-8830.2209127.
本文引用的文献
1
Hospitalisation and associated costs of gastrointestinal bleeding from primary prevention aspirin use in South Australia: a retrospective case series analysis.南澳大利亚州原发性预防使用阿司匹林导致胃肠道出血的住院情况及相关费用：一项回顾性病例系列分析
Intern Med J. 2022 Feb;52(2):318-321. doi: 10.1111/imj.15687.
2
[The expert consensus on diagnosis and acute-phase treatment of Kawasaki disease].[川崎病诊断与急性期治疗专家共识]
Zhonghua Er Ke Za Zhi. 2022 Jan 2;60(1):6-13. doi: 10.3760/cma.j.cn112140-20211018-00879.
3
Clinical Features in Children With Kawasaki Disease Shock Syndrome: A Systematic Review and Meta-Analysis.川崎病休克综合征患儿的临床特征：系统评价与荟萃分析
Front Cardiovasc Med. 2021 Sep 21;8:736352. doi: 10.3389/fcvm.2021.736352. eCollection 2021.
4
Treatment of Kawasaki Disease: A Network Meta-Analysis of Four Dosage Regimens of Aspirin Combined With Recommended Intravenous Immunoglobulin.川崎病的治疗：阿司匹林四种剂量方案联合推荐静脉注射免疫球蛋白的网状Meta分析
Front Pharmacol. 2021 Aug 12;12:725126. doi: 10.3389/fphar.2021.725126. eCollection 2021.
5
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease.意大利儿科学会关于川崎病一般治疗的修订建议。
Ital J Pediatr. 2021 Jan 25;47(1):16. doi: 10.1186/s13052-021-00962-4.
6
Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review.川崎病急性期低剂量或无阿司匹林治疗：荟萃分析和系统评价。
Arch Dis Child. 2021 Jul;106(7):662-668. doi: 10.1136/archdischild-2019-318245. Epub 2020 Nov 10.
7
Revision of diagnostic guidelines for Kawasaki disease (6th revised edition).川崎病诊断指南（第6版修订版）修订内容
Pediatr Int. 2020 Oct;62(10):1135-1138. doi: 10.1111/ped.14326. Epub 2020 Oct 1.
8
High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.高剂量与低剂量静脉注射免疫球蛋白治疗体重25公斤及以上川崎病患儿的疗效比较
Eur J Pediatr. 2020 Dec;179(12):1901-1907. doi: 10.1007/s00431-020-03794-2. Epub 2020 Aug 29.
9
Kawasaki disease shock syndrome: A report of two cases and literature review.川崎病休克综合征：两例报告及文献综述。
Pediatr Investig. 2019 Jun 25;3(2):81-85. doi: 10.1002/ped4.12127. eCollection 2019 Jun.
10
JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease.《日本循环学会/日本小儿循环学会2020年川崎病心血管后遗症诊断与管理指南》
Circ J. 2020 Jul 22;84(8):1348-1407. doi: 10.1253/circj.CJ-19-1094. Epub 2020 Jul 8.
Zotero 插件